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Dendritic cells (DCs) have the striking ability to cross-
present exogenous antigens in association with
major histocompatibility complex (MHC) class I to
CD8+ T cells. However, the intracellular pathways
underlyingcross-presentation remain ill defined.Cur-
rent models involve cytosolic proteolysis of antigens
by the proteasome and peptide import into endo-
plasmic reticulum (ER) or phagosomal lumen by the
transporters associated with antigen processing
(TAP1 and TAP2). Here, we show that DCs expressed
an ER-resident 47 kDa immune-related GTPase,
Igtp (Irgm3). Igtp resides on ER and lipid body (LB)
membranes where it binds the LB coat component
ADFP. Inactivation of genes encoding for either Igtp
or ADFP led to defects in LB formation in DCs and
severely impaired cross-presentation of phagocy-
tosed antigens to CD8+ T cells but not antigen pre-
sentation to CD4+ T cells. We thus define a new
role for LB organelles in regulating cross-presenta-
tion of exogenous antigens to CD8+ T lymphocytes
in DCs.
INTRODUCTION
Dendritic cells (DCs) are highly specialized antigen-presenting
cells endowed with the ability to prime or tolerize antigen-
specific naive T cells (Steinman et al., 2003). CD8+ T cells recog-
nize endogenous antigens (Ags) as short peptides associated
with major histocompatibility complex class I (MHC I). Antigenic
peptides arising from proteasomal degradation are translocated
into the endoplasmic reticulum (ER) lumen by transporters asso-
ciated with Ag processing (TAP1 and 2). Once in the ER, the
peptides undergo amino-terminal trimming by ER-associated
amino peptidases and are loaded on neosynthesized MHC I232 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.molecules by a complex, which is composed of calreticulin,
tapasin, and ERp57 (Cresswell et al., 2005).
DCs can also present exogenous Ags in association with
MHC I by a process called ‘‘cross-presentation’’ (Cresswell
et al., 2005). Ag uptake by macropinocytosis (Norbury et al.,
1997), receptor-mediated endocytosis (Bonifaz et al., 2002;
Regnault et al., 1999), and phagocytosis (Kovacsovics-Bankow-
ski and Rock, 1995) all initiate efficient cross-presentation.
Despite the importance of cross-presentation in tolerance and
infectious immunity (Steinman et al., 2003; Steinman and Nus-
senzweig, 2002), the cellular pathways underlying this process
are not fully understood. In most experimental systems, cross-
presentation relies on cytosolic processing events because it
can be blocked by pharmacological inhibition of the proteasome
and requires functional TAP transporters (Kovacsovics-Bankow-
ski and Rock, 1995). Indeed, there is considerable evidence that
exogenous Ags can access the cytosol after phagocytosis
(Kovacsovics-Bankowski and Rock, 1995), macropinocytosis
(Norbury et al., 1997), or receptor-mediated endocytosis (Boni-
faz et al., 2002; Rodriguez et al., 1999). The mechanisms under-
lying the delivery of Ags to the cytosol are ill understood but may
involve the ERAD pathway, which targets misfolded, lumenal ER
proteins to proteasomal degradation (Ackerman et al., 2006).
Nevertheless, it remains unclear whether ERAD-mediated retro-
translocation operates from the ER (after retrograde transport of
endocytosed Ag) (Ackerman et al., 2005) or from the endocytic
pathway (after recruitment of ER to endosomes and phago-
somes) (Ackerman et al., 2003; Burgdorf et al., 2008; Guermon-
prez et al., 2003; Houde et al., 2003). In addition, a wealth of
evidence supports the idea that cross-presentation is also
favored by the low proteolytic activity of the endocytic pathway
in DCs (Hotta et al., 2006; Lennon-Dumenil et al., 2002; Savina
et al., 2006). Finally, DEC-205 or mannose-receptor-dependent
retention of Ags in the early endocytic pathway favors cross-
presentation (Bonifaz et al., 2002; Burgdorf et al., 2007, 2008).
However, the precise coordination of endocytic and cytosolic
events leading to Ag proteolysis and MHC I loading during
cross-presentation remains to be established.
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components of the transport pathways that control cross-
presentation. GTPases are natural candidates, because they
act as major regulators of intracellular traffic. Among those
with dedicated immune function is a new family of 47 kDa immu-
nity-related GTPases (p47 GTPases) related to the dynamin
superfamily and regulating vesicular trafficking (MacMicking,
2004; Shenoy et al., 2007). Recent genetic analysis has estab-
lished that p47 GTPases exert pathogen-specific immunity to
infectious agents occupying a vacuolar niche in both human
and mouse settings (MacMicking, 2004; Shenoy et al., 2007).
One p47 GTPase in particular, Igtp (Irgm3), was found to reside
extensively within the ER (Taylor et al., 1996, 1997) and is critical
for interferon (IFN)-dependent immunity to Toxoplasma gondii
(Ling et al., 2006; Taylor et al., 2000). However, whether Igtp
contributes to adaptive immunity remains unknown.
In this study, we show that Igtp controls cross-presentation in
DCs. We found that Igtp-deficient DCs exhibited a major impair-
ment in their ability to cross-present phagocytic Ag to CD8+ but
not to present Ag to CD4+ T cells. The role of Igtp in the cross-
presentation pathway relied on intracellular events, because
Igtp-deficient DCs still phagocytosed Ag particles and interacted
with T cells with the same efficiency as their wild-type (WT) coun-
terparts. We demonstrate that Igtp localized to ER membranes
but also, unexpectedly, to lipid bodies (LBs). LBs (also called
lipid droplets) are neutral lipid storage organelles composed of
a central core of cholesteryl esters and triglycerides surrounded
by a single layer of phospholipids, which are thought to originate
from ER membranes (Fujimoto et al., 2008).
Igtp controlled LB accumulation in DCs after activation both
in vitro and in vivo. Complementation of Igtp-deficient DCs
by retroviral infection restored both LBs and efficient cross-
presentation, which suggests that LBs have a direct effect on
cross-presentation. In addition, we show that pharmacological
inhibition of diacylglycerol acyltransferase decreased LB accu-
mulation in DCs and inhibited cross-presentation.
ADFP belongs to the group of PAT (perilipin, ADFP, and
TIP47)-domain-containing proteins that regulate LB biogenesis
and dynamics (Brasaemle, 2007; Brasaemle et al., 1997; Chang
et al., 2006; Fujimoto et al., 2008). We identified the LB coat
protein ADFP as a partner of Igtp: Igtp physically interacted
and colocalized with ADFP in LBs in DCs. This interaction was
functionally relevant because accumulation of LB driven by
Igtp required ADFP. Finally, inactivation of the gene encoding
for ADFP markedly inhibits both LB accumulation and cross-
presentation of phagocytosed Ags by DCs. Taken together,
these results identify LBs as key organelles that regulate
cross-presentation of phagocytosed Ags in DCs.
RESULTS
Igtp Expression in DCs
Previous studies have shown that the expression of Igtp is
uniformly low in various cell types and further increased by IFN
exposure (MacMicking et al., 2003; Taylor et al., 2000, 1996).
Thus we wanted to determine whether Igtp is expressed in DCs.
Using RT-PCR and immunoblot, we found constitutive expres-
sion of Igtp in monocyte-derived DCs (mDCs, Figures 1A and
1B). IFN-g induced a dramatic increase in Igtp expression inmDCs (Figures 1A and 1B). Importantly, the basal expression
of both Igtp mRNA and protein was 10-fold higher in untreated
mDCs as compared to bone marrow-derived macrophages
(Figures 1A and 1B). Moreover, Igtp mRNA and protein were
detected in both CD8+ and CD8 DCs purified from mouse
spleen (Figures 1A and 1C). Finally, injection of the IFN-inducer
polyI:C in mice led to an increase of Igtp protein (Figure 1C).
Thus, Igtp is constitutively expressed by DCs and further
increased upon activation.
Role of Igtp in Cross-presentation
We found that Igtp deficiency did not impair the differentiation of
mDCs in granulocyte macrophage colony-stimulating factor
(GM-CSF)-dependent cultures, their cell-surface phenotype, or
their ability to respond to LPS (Figure S1 available online). For
the examination of the contribution of Igtp in Ag presentation,
mDCs were pulsed with ovalbumin (OVA)-coated latex beads
for 20 min, washed, chased for 5 hr, and fixed before incubation
with OVA-specific CD8+ OT-I-transgenic T cells whose activa-
tion was monitored by CD69 upregulation. As shown in Fig-
ure 1D, Igtp/ mDCs were unable to efficiently cross-present
OVA after latex bead phagocytosis. Indeed, a 4-fold increase
in OVA concentration on the beads was required to reach the
same efficiency of cross-presentation as in control mDCs (Fig-
ure 1D). In line with the normal expression of MHC I and costimu-
latory molecules (Figure S1), Igtp/ mDCs were not impaired in
their ability to activate OT-I T cells after pulsing with OVA MHC I
peptide (Figure 1E). Next we explored the possibility that Igtp/
mDCs were also defective for the MHC II Ag presentation
pathway. We found that Igtp/ mDCs were equivalent to WT
mDCs in their ability to activate OVA-specific OT-II-transgenic
CD4+ T cells after OVA latex bead phagocytosis or OVA MHC
II peptide loading (Figures 1F and 1G). These results indicate
that Igtp/ mDCs have a selective defect for cross-presentation
in vitro, whereas MHC II-restricted Ag presentation is unaffected.
To assess the contribution of Igtp to cross-presentation by
lymphoid organs DCs in vivo, we subcutaneously injected WT
or Igtp/ mice with OVA coupled to an anti-DEC205 (Bonifaz
et al., 2002). As shown in Figure 1H, cross-presentation of tar-
geted OVA to adoptively transferred OT-I T cells was slightly
but significantly reduced in Igtp/ mice when compared with
their WT counterparts (p < 0.001). Ex vivo sorting of total
lymphoid organ DCs loaded in vivo with anti-DEC-OVA conju-
gates (or high doses of soluble OVA) and in vitro coculture with
OT-I T cells further confirmed that Igtp/ DCs displayed slightly
reduced cross-presentation in situ (Figures S2 and S3). The
contribution of Igtp to normal cross-presentation in these
systems, however, was smaller than in mDCs (see above).
To examine the role of Igtp in phagocytic cross-presentation
by activated DCs, we compared the ability of WT and Igtp/
mice to cross-prime endogenous CD8+ T cells after intravenous
injection of apoptotic bodies loaded with OVA+polyI:C (Schulz
et al., 2005). PolyI:C, a viral double-stranded RNA mimetic
recognized by TLR-3, increases Igtp expression in splenic DCs
(Figure 1C). T cell cross-priming of endogenous CD8+ T cells
was decreased in Igtp/ mice when compared with WT mice
(Figure 1I, p < 0.005).
To assess the ability of Igtp/ mice to mount an endogenous
CD8+ T cell response, we infected WT or Igtp/ mice withImmunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 233
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Cross-presentation
(A) Relative Igtp mRNA expression in DCs (mDCs and
spleen DCs) and bone marrow macrophages (BMMs)
was measured by RT-PCR after 4 hr culture in the pres-
ence or not of recombinant IFN-g. Histograms represent
mean ± standard error of the mean (SEM) of three inde-
pendent experiments.
(B) Immunoblot analysis of Igtp and b-actin expression in
cell lysates from mDCs and BMMs cultured in the pres-
ence or not of IFN-g for 4 hr. mDCs derived from Igtp/
mice are used as a negative control. In the lower panel,
a densitometric quantification of Igtp signal intensity
normalized to b-actin loading control is shown (three
experiments, mean ± SEM).
(C) Immunoblot analysis of Igtp expression in cell lysates
from CD11c+ spleen DCs subsets sorted on CD8 expres-
sion (upper panel) or total spleen DCs sorted 8 hr after the
injection of 50 mg polyI:C (lower panel). a-tubulin is shown
as a loading control. A representative experiment is
shown.
(D and E) In vitro cross-presentation of OVA:BSA-coated
beads (D) and MHC I OVA peptide loading by WT or
Igtp/ mDCs (E). CD8+ T cell activation was determined
by the measurement of CD69 upregulation after overnight
incubation with fixed mDCs. Mean ± SEM of triplicate
cultures is shown.
(F and G) In vitro MHC II presentation of OVA:BSA-coated
beads (F) and MHC II OVA peptide loading by WT or
Igtp/ mDCs (G). CD4+ T cell proliferation was deter-
mined by CFSE dilution after 3 days of coculture with fixed
mDCs. Mean ± SEM of triplicate cultures is shown.
In (D)–(G), a representative experiment out of three (each
one performed in triplicates) is shown.
(H) In vivo cross-presentation after subcutaneous immuni-
zation of WT or Igtp/ mice with anti-DEC205-OVA. In
situ cross-presentation was monitored by CD69 upregula-
tion in adoptively transferred anti-OVA OT-I transgenic
cells at day 1, and nondraining (nd LN) and draining
(d LN) lymph nodes were analyzed (left panel). Results
from three independent experiments are represented
(right panel). Each dot represents an individual mice, and
the bar represents the mean.
(I) In vivo cross-priming in WT or Igtp/ mice immunized
with polyI:C- and OVA-loaded apoptotic bodies. Anti-
OVA polyclonal CD8+ T cell response was monitored at
day 8 after OVA peptide restimulation and IFN-g intracel-
lular staining (left panel). Data from three independent
experiments are represented (right panel). Each dot repre-
sents an individual mouse, and the bar represents the
mean.
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Lipid Bodies and Cross-presentationListeria monocytogenes-secreting OVA in the cytosol of infected
cells. We found no significant difference in the activation of
OVA-specific polyclonal CD8+ T cells in WT and Igtp/ mice
(Figure S4). We conclude that the CD8+ T cell compartment is
normal in Igtp/ mice, and that their DCs are competent to
present OVA if large quantities of this Ag are delivered into the
cytosol directly. Taken together, these results identify Igtp as
a positive regulator of cross-presentation in vitro and in vivo.
Igtp Does Not Control Phagocytosis but Does Delay
Phagosomal Maturation
To begin dissecting the mechanism underlying the role of Igtp
in cross-presentation, we analyzed phagosomal function in
Igtp/ mice. First we assessed the efficiency of Igtp/ mDCs in
performing phagocytosis, by using a stringent flow-cytometry-
based assay quantifying only internalized beads (Figure S5).
Control and Igtp/ mDCs display the same efficiency of phago-
cytosis (Figure 2A). Thus, Igtp is not involved in the phagocytosis
of latex beads. Accordingly, Ag presentation by MHC II is not
impaired in Igtp/ mDCs (Figure 1F).
Because Igtp did not impact the efficiency of Ag uptake, we
hypothesized that Igtp might modify phagosomal maturation.
Despite Igtp localization to ER (Taylor et al., 1997), we did not
observe any difference in the transient association of calnexin
to early phagosomes from control or Igtp/ mDCs (Ackerman
et al., 2003; Gagnon et al., 2002; Guermonprez et al., 2003;
Houde et al., 2003) (data not shown). Next we tested whether
Igtp controls the dynamics of phagolysosomal maturation.
Control or Igtp/ mDCs were incubated with OVA-crosslinked
latex beads for 10 min and washed, and their phagosomes
were analyzed at various time points by flow cytometry. We
found that phagosomes from Igtp/ mDCs exhibit an acceler-
ated acquisition of the phagolysosomal marker LAMP2, as well
as an increased degradation of phagosomal OVA (Figures 2B
and 2C). Thus, Igtp acts as a negative regulator of phagosomal
maturation.
Igtp Localizes to the ER and LBs
To gain further insight into the intracellular mechanisms under-
lying Igtp involvement in cross-presentation, we first investi-
gated the subcellular distribution of Igtp in IFN-g-treated
mDCs by immunofluorescence. As previously shown in other
cell types (Taylor et al., 1997), a small percentage of Igtp colocal-
ized with calnexin-positive ER, including perinuclear membrane
(Figure 3A). Much more pronounced staining, however, was
noted on spherical cytosolic donut-shaped structures of large
size (0.5–2 mm), completely devoid of calnexin (Figure 3A).
MHC I staining revealed a strong accumulation in the perinu-
clear area characteristic of Golgi apparatus, but did not colocal-
ize with the Igtpbright vesicles (Figure 3B). Using mDCs from MHC
II-GFP knockin mice (Boes et al., 2002), we did not find any
colocalization between the Igtpbright vesicles and MHC II-positive
compartments (Figure 3C). Lastly, Igtpbright vesicles did not stain
with the endolysosomal marker LAMP1 (Figure 3D), nor with
endocytic compartments labeled with 10 kD fluorescent dextran
tracers that had been chased for 20 min and followed up to 240
min after uptake (Figure 3E). Thus, Igtpbright vesicles were not ER
or MHC I or II transport vesicles, nor intermediates of the endo-
cytic network.Figure 2. Igtp Does Not Control Phagocytosis but Does Delay
Phagosomal Maturation
(A) Phagocytosis assay. WT or Igtp/ mDCs were incubated for 10 min with
various amounts of latex beads labeled with Alexa-488 and analyzed by flow
cytometry in the presence of trypan blue to quench the fluorescence of extra-
cellular beads. In the right panel, cells were pretreated with CytochalasinD to
prevent phagocytosis. Numbers indicate the percentage of phagocytic cells
for each condition.
(B and C) Phagosomal maturation assay. WT or Igtp/ mDCs were fed with
OVA covalently linked to 3 mm latex beads for 10 min, washed to remove
free beads, and left in culture for various time lapses. After hypoosmotic lysis
and fixation, 104 phagosomes were analyzed by flow cytometry after staining
with (B) anti-LAMP2 antibodies or (C) anti-OVA antibodies. Graphs indicate
a quantification of the percentage of phagosomes (B) positive for LAMP2
and (C) harboring degradated OVA at various time points. A representative
experiment is shown.Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 235
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Lipid Bodies and Cross-presentationBecause of their morphology, we hypothesized that these
vesicles were lipid bodies (LBs) or lipid droplets. A striking
feature of LBs is that they are composed of a dense hydrophobic
core of neutral lipids, surrounded by a hemimembrane, that do
not support the insertion of transmembrane proteins (Fujimoto
et al., 2008). The lipophilic dye Bodipy 493/503 (Bodipy) specif-
ically stains the neutral lipids that form the core of the LB. Using
this probe, we identified Igtpbright structures as LBs (Figures 4A
and 4B). Usually, Igtp LBs are localized in the periphery of the
cells and are sometimes close to or in direct contact with the
perinuclear ER (Figure 4A). The cores of the LBs were stained
with Bodipy, whereas Igtp was concentrated at the periphery
of these organelles (Figure 4B). Igtp localization to LBs increased
with LB numbers (Figure S6). Therefore, LBs represent a new
intracellular localization for Igtp, in addition to the previously
described ER localization.
Figure 3. Igtp Associates to ER andVesicles
that Are Distinct from ER and Endosomes
(A) IFN-g treated WT mDCs were fixed and stained
in immunofluorescence for Igtp and calnexin.
Fluorescence for both stainings was recovered at
various focal planes of a representative cell
(Z sections). Graphs represent the quantification
of Igtp (red line) and calnexin (green line) fluores-
cence intensity along the white lines drawn in the
merged image (linescan).
(B) IFN-g-treated WT mDCs were fixed and stained
for Igtp and the cytosolic tail of H-2Kb MHC I mole-
cules.
(C) IFN-g-treated mDCs derived from MHC II-GFP
knockin mice were fixed and stained for Igtp.
(D) IFN-g-treated mDCs were fixed and stained for
Igtp and LAMP1.
(A–D) Fluorescence for Igtp staining was recov-
ered in the red channel; fluorescence for other
stainings (calnexin, MHC class I, and LAMP1)
was recovered in the green channel. Fluorescence
images of each staining pseudocolored in white for
clarity are shown in the left and middle panels; an
overlay of both red and green images is shown
on the right panel.
(E) Igtpbright structures are distinct from endocytic
compartments accessible to exogenous 10 kD
dextrans. Cells were pulsed for 20 min with green
fluorescent dextrans, extensively washed, and
left in culture for various time points before fix-
ation and staining with anti-Igtp antibodies (red
channel). Overlay immunofluorescence images of
Igtp (red) and dextrans (green) are shown for
various time points after dextran uptake.
For all immunofluorescence experiments, cell
stainings representative of multiple experiments
are shown.
Because phagosomal maturation and
phagocytic cross-presentation are de-
pendent on Igtp, we sought to determine
whether Igtp could also be recruited to
phagosomes. We did not detect any
strong recruitment of Igtp in phagosomes
from mDCs at any time points after
phagocytosis (up to 240 min, Figure 4C).
In contrast, we often found Igtp- and Bodipy-positive LBs con-
tacting phagosomes (20.9% at 60 min phagocytic pulse, Figures
4C and 4D). The percentage of phagosomal association
decreased slightly after 3 hr of phagosomal maturation reaching
14.3% of the phagosomes (Figure 4D).
Igtp, together with Irga6, has been proposed to disrupt Toxo-
plasma gondii vacuole by a direct effect on vacuolar membranes
(Ling et al., 2006; Martens et al., 2005). We did not detect any
membranolytic activity for Igtp on synthetic membranes (Fig-
ure S7). Together with the lack of enrichment of Igtp on phago-
somes, this finding does not support the idea that Igtp may
control the delivery of phagosomal antigens to the cytosol by
acting directly at the level of phagosomal membranes.
In summary, Igtp is mostly associated with LBs. This finding
led us to investigate the possibility that Igtp controls LB accumu-
lation in DCs.236 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.
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For the quantification of LB accumulation under basal conditions,
WT and Igtp/ mDCs were stained with Bodipy (Figure 5A). We
found that the number of LBs per cell was significantly decreased
in Igtp/ when compared to control mDCs (Figure 5A; median
WT = 1 versus Igtp/ = 0; p < 0.0001). Twice as many Igtp/
mDCsweredevoidofany LBs ascompared tocontrols (FigureS8).
Because IFN-g increased Igtp expression (Figure 1), we tested
the effect of IFN-g treatment on LB accumulation. We found
Figure 4. Igtp Associates to LBs
(A) Igtp surrounds Bodipy-positive lipid bodies (LBs). IFN-
g-treated WT mDCs were fixed and stained with antibody
specific for Igtp and the LB-specific probe Bodipy.
(B) Detail of Igtp-positive LB showing the surrounding ring
of Igtp and the dense core of the LB stained with Bodipy.
The graph represents the quantification of Igtp (red line)
and Bodipy (green line) fluorescence intensity of a repre-
sentative LB.
(C) WT mDCs were fed with 3 mM latex beads for 30 min,
then washed and cultured for 60 min. Cells were fixed,
and the distribution of Igtp-positive lipid bodies was
analyzed by staining as in (A).
(D) Detail of LB-phagosome contact sites. A quantification
of phagosomes contacting Igtp-positive LBs at two time
points after the uptake of beads is shown.
a major increase in the median number of LBs
in IFNg-treated mDCs as compared to
untreated WT mDCs (Figure 5A; median WT = 1
versus WT+IFN-g = 6). This increase was almost
completely lost in the absence of Igtp (Figure 5A;
median WT+IFN-g = 6 versus Igtp/ = 1;
p < 0.0001). Igtp/ mDCs were not able to
accumulate more than ten LBs per cell
(Figure S8, middle panel). These findings
demonstrate that Igtp is a major regulator of
LB accumulation in IFN-g-activated mDCs.
In order to determine whether LBs accumu-
late in the conditions of our cross-presentation
assays, we counted LBs in mDCs exposed to
OVA-coated latex beads. We found a significant
increase in LBs in OVA-coated latex-bead-
exposed WT mDCs as compared to controls
(Figure 5A, median WT = 1 versus WT+OVA
beads = 5). OVA-bead-dependent increase
was almost completely absent in the case of
Igtp/ mDCs (Figure 5A, median Igtp/ = 0
versus Igtp/+OVA beads = 1). In addition,
Igtp/ mDCs exposed to beads accumulated
only up to five LBs per cell, whereas many
control mDCs harbored more than 15 LBs per
cell (Figure S8, lower panel).
To obtain larger sample quantitation of LB
accumulation, we analyzed Bodipy-labeled DCs
by flow cytometry. This method measures the
LB amount at the single-cell level in a large
number of cells. As shown in Figure 5B, the
Bodipy signal was slightly higher in control
mDCs when compared to Igtp/ mDCs. Impor-
tantly, the increase in LB accumulation in IFN-g-induced or latex-
bead-pulsed WT mDCs was not observed in the absence of Igtp
(Figure 5B).
In splenic DCs, we observed that CD8+ DCs have more LBs
than their CD8 counterparts in WT mice (Figure 5C, 37% reduc-
tion, p < 0.0001). These data are compatible with the idea that
LBs may participate in cross-presentation, because CD8+ DCs
are more efficient than their CD8 counterparts in cross-presen-
tation of phagocytosed Ag (den Haan et al., 2000; Iyoda et al.,Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 237
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Lipid Bodies and Cross-presentation2002; Schnorrer et al., 2006). Igtp/ DCs exhibit a slight defect
in LB accumulation both in the CD8+ subset (p < 0.05) and in the
CD8 subset (p < 0.005). Activation induced by in vivo injection
of polyI:C induced efficient maturation both in control and
Igtp/ mice (Figure S9) and also induced Igtp expression in
control mice (Figure 1C). PolyI:C induced a net increase in the
Figure 5. Igtp Controls LB Accumulation in
DCs
(A) Representative immunofluorescence images of
LB staining (Bodipy) in fixed WT or Igtp/ DCs
after IFN-g treatment. LBs were quantified in
DCs. A representative experiment out of three is
shown (70 to 200 cells were analyzed for each
condition in each experiment). WT DCs or Igtp/
DCs untreated, treated with IFN-g, or pulsed with
OVA beads were analyzed. Each symbol repre-
sents one cell. Statistical significance was
assessed with the Mann-Whitney test.
(B) Bodipy flow-cytometry analysis of CD11c+
mDCs. WT (black lines) and Igtp/ DC (red lines)
untreated, treated with IFN-g, or pulsed with OVA
beads were analyzed. Mean fluorescence-inten-
sity values of Bodipy staining from three indepen-
dent experiments were normalized and plotted as
the mean ± SEM (WT+IFN-gMFI = 196 ± 10 versus
Igtp/+IFN-g MFI = 84 ± 7, p < 0.05, t test;
WT+OVA beads MFI = 133 ± 11 versus Igtp/+
OVA beads MFI = 78 ± 13, p < 0.001, t test).
(C) Bodipy flow-cytometry analysis of CD11c+
CD8+ and CD11c+CD8 splenic DCs from WT or
Igtp/ mice untreated or 12 hr after an intrave-
nous injection of 50 mg polyI:C. Histogram plots
represent activated CD11c+CD8+ (upper panel)
and CD11c+CD8 (lower panel) from WT (black)
and Igtp/ (red) mice. Mean fluorescence-inten-
sity values of Bodipy staining from three indepen-
dent experiments were normalized to the WT
untreated CD11c+CD8+ population and plotted
as the mean ± SEM (CD8+ WT = 100 ± 3.9, CD8+
Igtp/ = 82.5 ± 7.5, CD8 WT = 63.1 ± 2.6,
CD8Igtp/ = 48.5 ± 4.1, CD8+ WT+polyI:C =
132.3 ± 11, CD8+ Igtp/+polyI:C = 79.4 ± 8.2,
CD8 WT+polyI:C = 79.2 ± 6.7, CD8Igtp/+
polyI:C = 45.2 ± 5.1, t test).
LB accumulation of CD8+ DCs (p <
0.005) and, to a lesser extent, in the
CD8 DCs (p < 0.05) (Figure 5C). By
contrast, Igtp/ DCs were unable to
increase LB accumulation in response
to polyI:C in both subsets. As a result,
the difference between control and
Igtp/ DCs increased after activation,
leading to a 47% reduction in the CD8+
subset (p < 0.05) and a 66% reduction
in the CD8 subset (p < 0.05) (Figure 5C).
Collectively, our results demonstrate
that Igtp is important in the establishment
of the LB pool in DCs. Igtp induction pro-
motes LB accumulation after DC stimula-
tion (mDCs after IFN-g, polyI:C in splenic
DCs). Igtp-dependent effects appear
specific for immune stimulation because the induction of LBs
by oleic acid feeding was not compromised in Igtp/ mDCs,
which suggests that the basal LB-producing machinery is not
impaired in Igtp/ cells (Figure S10). These results identify
Igtp as an immune regulator of LB accumulation and suggest
that LBs may facilitate cross-presentation.238 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.
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The results presented so far showed a role for Igtp in both cross-
presentation and the control of LB accumulation in DCs. These
findings led us to investigate the possibility that a connection
exists between these two processes. To distinguish whether
Igtp impacts the cross-presentation by altering mDC develop-
ment, we reintroduced Igtp in Igtp/ DCs. Retrovirally trans-
duced Igtp/ mDCs expressed the protein that localized to
LBs and increased LB amounts (Figures 6A–6C).
To test whether Igtp complementation would restore cross-
presentation, we retrovirally transduced Igtp/ mDCs pulsed 30
min with OVA-coated beads. After 6 hr, cells were washed and
incubated with OT-I T cells overnight. As shown in Figure 6D, the
cross-presentationdefectof Igtp/mDCs was partially corrected
by the Igtp-encoding virus, but not the control virus. We conclude
that the effect of Igtp on cross-presentation is independent of any
additional unknown effect that it might have on DC development.
To determine whether the LB accumulation in DC correlates
with the efficiency of cross-presentation, we compared mDCs
that were distinct in their LB accumulation but identical in Ag
load. mDCs harboring one OVA bead were sorted by flow cytom-
etry according to their ‘‘low’’ or ‘‘high’’ LB accumulation and
cocultured with OT-I T cells for 18 hr (Figure 6E). We found far
more efficient cross-presentation within the LB high population
even though the two DC populations expressed similar amounts
of CD86 and activated OT-I T cells upon OVA MHC I peptide
loading similarly (Figure 6F, Figure S11). We conclude that the
total intracellular accumulation of LBs measured by Bodipy fluo-
rescence correlates with cross-presentation by mDCs.
To further probe the requirement of LBs in cross-presentation,
we designed a second approach aimed at reducing LB amounts
by inhibiting Acyl CoA:diacylglycerol acyltransferase (DGAT),
which produces triglyceride stores. Xanthohumol has been iden-
tified as a DGAT inhibitor (Tabata et al., 1997). mDCs were fed
with OVA-coated latex beads or pulsed with OVA MHC I peptide
for 30 min, washed, and then cultured for 4 hr with Xanthohumol
at 85 mM, which resulted in a 30%–50% inhibition of LB as
measured by flow cytometry (Figure 6G, Figure S12). Cells
were then washed and fixed before overnight incubation with
OT-I T cells. Xanthohumol inhibited cross-presentation of OVA-
coated latex beads by 44% at the highest dose of beads and
by 51% at the lowest dose of beads (p < 0.001 in both cases)
but left unaffected the presentation of the OVA peptide (Figures
6 H and 6I). These experiments confirm that LBs are required for
normal cross-presentation by mDCs in vitro.
ADFP Interacts with Igtp and Is Required for LB
Formation and Efficient Cross-presentation
The way in which Igtp exerts its effects on LB biogenesis remains
unclear. However, recent yeast two-hybrid analysis found that
another p47 IRG, Irgd (IRG-47), interacts with the LB protein
ADFP (Yamaguchi et al., 2006). Loss of ADFP results in
decreased LB formation in hepatocytes and macrophages (Bra-
saemle et al., 1997; Chang et al., 2006; Fujimoto et al., 2008; Paul
et al., 2008). We found that ADFP is expressed in mDCs and co-
localizes on the same LBs as Igtp (Figure 7A). To investigate the
possibility that the two proteins interact directly, we performed
pull-down assays with GST-Igtp as bait. ADFP was immunopre-
cipitated efficiently with GST-Igtp but not with GST-Irgm1, GST,or glutathione beads alone (Figure 7B). Reciprocally, Myc-
tagged ADFP immunoprecipitated Igtp and the positive control,
Irgd, but not Irgm1 in mammalian cell extracts (Figure 7B).
Notably, interaction between Igtp and ADFP did not require
Igtp GTPase activity; a constitutive GDP-bound Igtp mutant
(IgtpS98N) still immunoprecipitated ADFP (Figure S13). These
findings fit with earlier observations showing that IgtpS98N
remains associated with membranes, suggesting that GTPase
activity is not required for steady-state localization (Taylor
et al., 1997).
Having identified ADFP as a partner for Igtp, we next asked
whether genetic lesions in Adfp phenocopy those of Igtp. In
contrast to Igtp/, Adfp/ mDCs exhibited a strongly de-
creased amount of LB even before activation (42% of decrease
in Bodipy mean fluorescence intensity [MFI], p < 0.005,
Figure 7C) and a reduced induction of LBs upon oleate feeding
(Figure S10). Because Igtp controls the upregulation of LB accu-
mulation upon IFN-g exposure (Figure 5), we sought to analyze
the LB accumulation of Adfp/ cells after IFN-g treatment. We
found that IFN-g-treated Adfp/ mDCs failed to upregulate
LBs as their WT counterparts (Figure 7D, p < 0.0001). This result
was confirmed by LB counting in immunofluorescence after
Bodipy staining (Figure 7E): after IFN-g treatment, the mean
number of LB was reduced from 6.4 LBs/cell in WT versus
3.1 LBs/cell in Adfp/ (p < 0.0001). We conclude that LB accu-
mulation after IFN-g treatment is dependent on ADFP, which
interacts with Igtp.
Previous studies identified a greater than 10-fold enrichment
of ADFP mRNA in CD8+ as compared to the CD8 spleen DC
subset (Dudziak et al., 2007; Edwards et al., 2003). At the protein
level, we found a two-fold enrichment of ADFP in the CD8+ DC
subset when compared to the CD8 DC subset (immunoblot,
Figure 7F; p < 0.05). Consistent with this observation, ADFP-
positive LBs were abundant in CD8+ DCs; in addition, Igtp and
ADFP colocalized on the same LBs (Figure S14).
We also found that Adfp/ splenic DCs were defective in LB
accumulation and even more so than Igtp/ DCs (Figure 7G).
We conclude that ADFP is required for LB accumulation in
splenic DCs.
To determine whether the loss of ADFP altered cross-presenta-
tion by splenic DCs, we compared OVA-bead cross-presentation
assays with WT, Igtp/, and Adfp/ splenic DCs. OT-I
T cell activation was decreased by approximately 50% when
they were activated by Adfp/ or Igtp/ DCs, as compared
to WT control (Figure 7H). ADFP deficiency had no effect on
cell-surface phenotype, on phagocytic ability, on the ability
to present OVA peptide to CD8+ T cells, or on DC maturation
(Figure S15 and data not shown). These experiments estab-
lish the convergence of Igtp- and ADFP-containing LBs as
regulatory organelles for the cross-presentation pathway in
DCs from lymphoid organs.
DISCUSSION
The present study identifies an IFN-inducible ER-resident
GTPase, Igtp (Irgm3), as a new component of the cross-presen-
tation pathway. Igtp-defective DCs failed to cross-present
phagocytosed Ag efficiently, whereas interaction with T cells,
phagocytosis, and presentation to CD4+ T cells remainImmunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 239
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Lipid Bodies and Cross-presentationFigure 6. A Role for LBs in Cross-presentation
(A–D) Restoration of LB accumulation and cross-presentation by Igtp complementation in Igtp/ mDCs. Differentiated Igtp/ mDCs were infected with pMx
control retrovirus or pMx-Igtp.
(A) Immunoblot from cell lysate after 24 hr culture.
(B) Flow-cytometry analysis after overnight culture of infected DCs with CD11c and Bodipy staining.
(C) Immunofluorescence performed with anti-Igtp staining (red) and the LB-specific Bodipy probe (green).
(D) Cross-presentation assay with Igtp/ mDCs infected after OVA-bead uptake with pMx or pMx-Igtp. mDCs were extensively washed and cultured with anti-
OVA OT-I CD8+ T cells. Cross-presentation was monitored by CD69 upregulation. Results of a representative experiment in triplicate cultures are plotted as mean
± SEM.
(E and F) Efficient cross-presentation is retained within the lipid body high fraction of WT mDCs.240 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.
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required for efficient cross-presentation. In addition to its docu-
mented residence in the ER (Taylor et al., 1997), we show that
Igtp associates with compartments distinct from the ER or endo-
some. Two characteristics define these vesicles as LBs: (1)
a dense core of neutral lipids stained by the LB-specific probe
Bodipy, and (2) an outer envelope covered with the LB-specific
coat protein ADFP. LBs are storage organelles for neutral lipids
such as cholesteryl esters or triglycerides (Fujimoto et al.,
2008). ADFP is sufficient to activate de novo formation of LBs
in adipocytes as well as other cell types when overexpressed
(Gao and Serrero, 1999). The removal of ADFP leads to hepatic
and macrophage LB deficiency in vivo (Chang et al., 2006;
Paul et al., 2008).
We found that Igtp controls the accumulation of LBs induced
by cell activation after various stimuli (IFN-g or polyI:C). This
induction appears to involve ADFP that physically associates
with Igtp during IFN-g-induced upregulation of LBs. Igtp may
participate in the neoformation of LBs by regulating the associa-
tion of ADFP with the LB outer membrane.
Alternatively, it may help stabilize a pre-existing interaction of
ADFP with LBs because Igtp itself does not appear to bind neutral
lipids directly (Tiwari et al., 2009). This latter interaction could
prevent the recruitment of cytosolic lipases (Brasaemle, 2007).
We provide several lines of evidence that show that LBs
are involved in cross-presentation: First, activation of LB accu-
mulation upon Igtp retroviral complementation increased
cross-presentation in Igtp/ mDCs. Second, depletion of LB by
pharmacological inhibition of DGAT inhibited cross-presentation
in WT mDCs. Third, ADFP deficiency led to decreased LB accu-
mulation and decreased cross-presentation. ADFP is very spe-
cifically associated with LBs (Brasaemle et al., 1997). In this
respect, the fact that both Igtp and ADFP are needed for
cross-presentation—two proteins structurally and phylogeneti-
cally dissimilar to one another—is likely to be explained on the
basis of their dual action at the level of LBs. This interpretation
is further reinforced by the almost exclusive colocalization of
these proteins to LBs and their ability to physically interact
in vitro and in vivo. In conclusion, three independent loss-of-
function approaches that perturb LB homeostasis—two genetic,
one pharmacologic—also disrupt cross-presentation in DCs.
Moreover, complementation or gain of function of at least one
of these components, Igtp, overturns such defects. These data
identify LBs as a positive regulator of the cross-presentation
pathway in DCs.
How and where do LBs exert their effects on the cross-presen-
tation pathway? Igtp (Irgm3) and Irga6 are both ER-associated
p47 GTPases that have been proposed to disrupt Toxoplasma
gondii parasitophorous vacuoles by triggering membrane vesic-ulation and fission (Ling et al., 2006; Martens et al., 2005). We did
not observe any strong association to phagosomes or any mem-
branolytic activity of recombinant Igtp on synthetic membranes.
This finding does not support the idea that Igtp promotes cross-
presentation through a direct destabilization of phagosomal
membranes enabling the delivery of phagosomal Ag to the
cytosol.
It has been proposed that the process of LB neoformation may
also promote the formation of transient lipidic pores at the level
of ER membranes (Ploegh, 2007). This could be in relation to
the established function of LBs as cytosolic sites for ubiquitina-
tion of ER-derived proteins (Fujimoto and Ohsaki, 2006). Further
studies are required to determine whether these processes
underlie the effect of Igtp and ADFP on cross-presentation of
phagocytosed Ag.
Here we show that Igtp negatively effects phagosomal matu-
ration both in terms of late marker acquisition (LAMP2) and
proteolytic activity (OVA degradation). Thus, besides other
mechanisms, the action of Igtp may participate in the establish-
ment of endocytic compartment endowed with a low proteolytic
activity favoring cross-presentation (Delamarre et al., 2005;
Hotta et al., 2006; Lennon-Dumenil et al., 2002; Savina et al.,
2006; Trombetta et al., 2003). The phagosome-LB contact sites
that we have identified may support a regulatory function of LBs
on phagolysosomal progression. Importantly, the negative effect
of Igtp on phagolysosomal progression is in line with its lack of
involvement in antimycobacterial innate immunity, which relies
on the activation of phagolysosomal function (MacMicking
et al., 2003).
LBs have already been described in DCs, including in the first
description of these cells (Maroof et al., 2005; Steinman and
Cohn, 1973). Our results have uncovered a unique aspect of
DC biology, related to lipid metabolism and its implication for
Ag cross-presentation by MHC I. Further studies are required
to identify the molecular pathways controlling the involvement
of LBs in cross-presentation in DCs.
EXPERIMENTAL PROCEDURES
See the Supplemental Data for details.
Mice
Igtp/ mice (Taylor et al., 2000), Adfp/ mice (Chang et al., 2006), OVA-
specific CD8+ (OT-I) an CD4+ (OT-II) TCR-transgenic mice, and MHC II-GFP
knockin mice (Boes et al., 2002) have been described previously. Live animal
experiments were done in compliance with the U.S. and French guidelines.
Cells and Ag Presentation Assays
Bone marrow-derived GM-CSF DCs (day 7–8) were used and termed mDCs.
For some experiments, Igtp expression was induced by 3–5 hr treatment(E) Flow-cytometry sorting of WT mDCs having phagocytosed one bead according to their LB content assessed by Bodipy staining. Two mDCs populations, the
Bodipy high (black line) and the Bodipy low (gray line), were sorted according to their intensity of staining for Bodipy.
(F) In vitro cross-presentation of OVA- or BSA-coated beads in Bodipy-high and -low DC populations was measured for different DC:T cells ratio. Cross-presen-
tation was monitored by CD69 upregulation. The mean of three independent experiments, each one normalized to maximal OT-I response, is shown (mean ± SEM).
(G–I) Pharmacological inhibition of lipid bodies inhibits cross-presentation in WT cells.
(G) Bodipy staining after gating on CD11c+ cells of mDCs treated for 4 hr with 85 mM Xanthohumol or the control concentration of DMSO.
(H) CD69 flow-cytometry histogram after gating on Va2+CD8+ of OT-I cells cultured overnight with fixed mDCs exposed to DMSO or 85 mM Xanthohumol for 4 hr
after Ag uptake.
(I) Quantification of OT-I T cell activation of a representative experiment performed in triplicate cultures (mean ± SEM).Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 241
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Lipid Bodies and Cross-presentationFigure 7. ADFP Interacts with Igtp and Controls LB Formation and Cross-presentation
(A) Immunofluorescence of WT mDCs treated with IFN-g fixed and stained for Igtp (red) and ADFP (green).
(B) On the left is an immunoblot (IB) of ADFP interactions with recombinant GST-Igtp and another p47 GTPase, GST-Irgm1, prebound to glutathione-Sepaharose
4B beads. GST and beads alone served as negative controls. Comparable levels of Myc-ADFP expression in HEK whole-cell lysates (WCLs, middle panel) before
incubation with purified GST-tagged proteins pre-bound to Sepharose beads are shown (bottom panel). A single asterisk denotes the position of cleaved GST-
Igtp in addition to the full-length protein after bead incubation. One of two experiments is shown. On the right, coimmunoprecipitation of Igtp with ADFP in human
HEK cells is shown. Immunoblot of EYFP-Igtp retrieved by Myc-ADFP on Protein G resin is shown. EYFP-Irgd and EYFP-C1 were used as positive and negative
controls, respectively (top panel). A double asterisk denotes low amounts of full-length EYFP-Igtp because of instability in whole-cell lysates (bottom panel). IgG-
HC denotes immunoglobulin G heavy chain, and IgG-LC denotes immunoglobulin G light chain. One of four similar experiments is shown.
(C) Flow-cytometry analysis after Bodipy staining of nonactivated CD11c+ mDCs from WT or Adfp/ mice (WT = 160.6 ± 15.3; Adfp/ = 91.6 ± 15.3, p < 0.05).
(D and E) LB quantification in WT or Adfp/ mDCs treated with IFN-g via Bodipy staining and (D) flow-cytometry analysis or (E) LB counting by immunofluores-
cence. In (D), results are normalized to 100 in the control cells (WT+IFN-g = 121.5 ± 5.6, Adfp/+IFN-g = 67.5 ± 6.6, p < 0.0001, t test). An example of flow-
cytometry analysis is shown. In (E), IFN-g-activated mDCs were fixed and submitted to LB counting by immunofluorescence after staining with the LB-specific
probe Bodipy (WT+IFN-g = 6.44 ± 0.36 n = 372, Adfp/+IFN-g = 3.38 ± 0.36, n = 393, p < 0.0001, t test).242 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.
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Lipid Bodies and Cross-presentationwith 250 ng/ml IFN-g. Spleen DCs (SDCs) were isolated from mouse spleens
after collagenase digestion, purified with CD11c magnetic beads (Miltenyi),
and further purified by fluorescence activated cell sorting. In vitro cross-
presentation assays were adapted from procedures previously described
(Guermonprez et al., 2003) and used CD69 upregulation in OT-I T cells as
a readout. For some experiments, mDCs were infected with pMx retrovirus
harboring Igtp cDNA (or control empty retrovirus) in the presence of polybrene
(10 mg/ml). DEC-OVA conjugates were prepared as previously described
(Bonifaz et al., 2002). For in vivo cross-priming assays, 30.107 splenic cells
from b2m-deficient mice were loaded endocytically by pulsing with 20 mg/ml
OVA plus 2 mg/ml polyI:C for 15 min prior to g irradiation and intravenous injec-
tion. Eight days later, spleens were harvested and IFN-g production by endog-
enous CD8+ T cells was measured after peptide-specific restimulation.
Phagosome Assays
For flow-cytometric analysis of phagosomes, 25.106 DCs were pulsed for 10
min at 37C at a ratio of 1:3 with 3 mm latex beads coupled covalently to
OVA by glutaraldehyde crosslinking. Then, cells were washed three times on
a serum gradient at 150 G (4C) before chase at 37C. After hypoosmotic lysis
and fixation, phagosomes were stained with anti-OVA or anti-LAMP2 anti-
bodies and analyzed by flow cytometry (Guermonprez et al., 2003).
LB Measurements and Immunofluorescences
After cell-surface staining, cells were fixed with PFA 1% and stained for LBs in
PermWash solution (Becton Dickinson) with BOPIDY FL (Molecular probes) at
4 mg/ml for flow-cytometry analysis and 10 mg/ml for immunofluorescences.
GST Pull-Down Assays
Recombinant p47 GTPases expressing GST tAg were immobilized on glutha-
thione sepharose and incubated with HEK lysates of transiently expressed
ADFP-myc for coimmunoprecipitation. In the reverse experiments, lysates of
HEK cells transfected with Myc-ADFP and various EYFP-tagged p47 GTPases
were immunoprecipitated with anti-Myc resin.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
fifteen figures and can be found with this article online at http://www.cell.
com/immunity/supplemental/S1074-7613(09)00325-2.
ACKNOWLEDGMENTS
The authors thank G. Taylor, H. Shen, Z. Maciorowski, C. Guerin, I. Grandjean,
A. Boissonnas, L. Saveanu, A. Savina, W. Faigle, D. Loew, B. Lombard, C.L.
Trubert, M. Merad, and S. Davis for reagents, helpful discussions, or critical
reading of the manuscript. L.B. was supported by the Association pour la
Recherche sur le Cancer, the Curie Institute, and INSERM. L.C. was supported
by the National Institutes of Health (NIH) Grant HL 51586. J.D.M. was sup-
ported by the NIH National Institute of Allergy and Infectious Diseases (R01
AI068041-01A1), the Burroughs Wellcome Fund Award, the Searle Foundation
(05-F-114), Cancer Research Institute, and the W.W. Winchester Foundation.
P.G. was supported by the Centre National de la Recherche Scientifique, the
Agence Nationale pour la Recherche, and the Rockefeller University.
Received: April 29, 2009
Revised: June 13, 2009
Accepted: June 18, 2009
Published online: August 20, 2009REFERENCES
Ackerman, A.L., Kyritsis, C., Tampe, R., and Cresswell, P. (2003). Early phag-
osomes in dendritic cells form a cellular compartment sufficient for cross
presentation of exogenous antigens. Proc. Natl. Acad. Sci. USA 100, 12889–
12894.
Ackerman, A.L., Kyritsis, C., Tampe, R., and Cresswell, P. (2005). Access of
soluble antigens to the endoplasmic reticulum can explain cross-presentation
by dendritic cells. Nat. Immunol. 6, 107–113.
Ackerman, A.L., Giodini, A., and Cresswell, P. (2006). A role for the endo-
plasmic reticulum protein retrotranslocation machinery during crosspresenta-
tion by dendritic cells. Immunity 25, 607–617.
Boes, M., Cerny, J., Massol, R., Op den Brouw, M., Kirchhausen, T., Chen, J.,
and Ploegh, H.L. (2002). T-cell engagement of dendritic cells rapidly rear-
ranges MHC class II transport. Nature 418, 983–988.
Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C., and
Steinman, R.M. (2002). Efficient targeting of protein antigen to the dendritic
cell receptor DEC-205 in the steady state leads to antigen presentation on
major histocompatibility complex class I products and peripheral CD8+
T cell tolerance. J. Exp. Med. 196, 1627–1638.
Brasaemle, D.L. (2007). Thematic review series: Adipocyte biology. The peril-
ipin family of structural lipid droplet proteins: Stabilization of lipid droplets and
control of lipolysis. J. Lipid Res. 48, 2547–2559.
Brasaemle, D.L., Barber, T., Wolins, N.E., Serrero, G., Blanchette-Mackie,
E.J., and Londos, C. (1997). Adipose differentiation-related protein is an ubiq-
uitously expressed lipid storage droplet-associated protein. J. Lipid Res. 38,
2249–2263.
Burgdorf, S., Kautz, A., Bohnert, V., Knolle, P.A., and Kurts, C. (2007). Distinct
pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell
activation. Science 316, 612–616.
Burgdorf, S., Scholz, C., Kautz, A., Tampe, R., and Kurts, C. (2008). Spatial and
mechanistic separation of cross-presentation and endogenous antigen
presentation. Nat. Immunol. 9, 558–566.
Chang, B.H., Li, L., Paul, A., Taniguchi, S., Nannegari, V., Heird, W.C., and
Chan, L. (2006). Protection against fatty liver but normal adipogenesis in
mice lacking adipose differentiation-related protein. Mol. Cell. Biol. 26,
1063–1076.
Cresswell, P., Ackerman, A.L., Giodini, A., Peaper, D.R., and Wearsch, P.A.
(2005). Mechanisms of MHC class I-restricted antigen processing and
cross-presentation. Immunol. Rev. 207, 145–157.
Delamarre, L., Pack, M., Chang, H., Mellman, I., and Trombetta, E.S. (2005).
Differential lysosomal proteolysis in antigen-presenting cells determines
antigen fate. Science 307, 1630–1634.
den Haan, J.M., Lehar, S.M., and Bevan, M.J. (2000). CD8(+) but not CD8(-)
dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685–
1696.
Dudziak, D., Kamphorst, A.O., Heidkamp, G.F., Buchholz, V.R., Trumpfheller,
C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.W., Park, C.G., et al. (2007).
Differential antigen processing by dendritic cell subsets in vivo. Science 315,
107–111.
Edwards, A.D., Chaussabel, D., Tomlinson, S., Schulz, O., Sher, A., and Reis e
Sousa, C. (2003). Relationships among murine CD11c(high) dendritic cell
subsets as revealed by baseline gene expression patterns. J. Immunol. 171,
47–60.(F) Immunoblot analysis of ADFP expression in cell lysates from CD8 and CD8+ spleen DC subsets. Densitometric quantification of ADFP signal intensity
rapported to the b-actin loading control (three independent experiments, mean ± SEM, statistical significance was assessed by t test).
(G) Flow-cytometry analysis of splenic DC subsets from WT or Adfp/ mice. Representative flow-cytometry fluorescence histograms of splenic CD11c+CD8
and CD11c+CD8+ subsets stained with Bodipy from WT (black lines) and Adfp/ (blue lines) are shown. Mean fluorescence-intensity values from three indepen-
dent experiments were plotted as the mean ± SEM (WT CD8 = 163.7 ± 18, Adfp/CD8 = 70.17 ± 7, p < 0.01, WT CD8+ = 234 ± 20, Adfp/CD8+ = 93.57 ± 1,
p < 0.005, t test).
(H) In vitro cross-presentation of OVA-coated beads by CD11c+ spleen DCs from WT (black), Igtp/ (red), andAdfp/ (blue). Cross-presentation is monitored by
CD69 upregulation in anti-OVA OT-I CD8+ T cells in three independent experiments, each one normalized to the maximal OT-I response (mean ± SEM).Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc. 243
Immunity
Lipid Bodies and Cross-presentationFujimoto, T., and Ohsaki, Y. (2006). Proteasomal and autophagic pathways
converge on lipid droplets. Autophagy 2, 299–301.
Fujimoto, T., Ohsaki, Y., Cheng, J., Suzuki, M., and Shinohara, Y. (2008). Lipid
droplets: A classic organelle with new outfits. Histochem. Cell Biol. 130,
263–279.
Gagnon, E., Duclos, S., Rondeau, C., Chevet, E., Cameron, P.H., Steele-
Mortimer, O., Paiement, J., Bergeron, J.J., and Desjardins, M. (2002). Endo-
plasmic reticulum-mediated phagocytosis is a mechanism of entry into macro-
phages. Cell 110, 119–131.
Gao, J., and Serrero, G. (1999). Adipose differentiation related protein (ADRP)
expressed in transfected COS-7 cells selectively stimulates long chain fatty
acid uptake. J. Biol. Chem. 274, 16825–16830.
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P., and
Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I cross-
presentation compartment in dendritic cells. Nature 425, 397–402.
Hotta, C., Fujimaki, H., Yoshinari, M., Nakazawa, M., and Minami, M. (2006).
The delivery of an antigen from the endocytic compartment into the cytosol
for cross-presentation is restricted to early immature dendritic cells. Immu-
nology 117, 97–107.
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A.,
Princiotta, M.F., Thibault, P., Sacks, D., and Desjardins, M. (2003). Phago-
somes are competent organelles for antigen cross-presentation. Nature 425,
402–406.
Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Taka-
hara, K., Steinman, R.M., and Inaba, K. (2002). The CD8+ dendritic cell subset
selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195,
1289–1302.
Kovacsovics-Bankowski, M., and Rock, K.L. (1995). A phagosome-to-cytosol
pathway for exogenous antigens presented on MHC class I molecules.
Science 267, 243–246.
Lennon-Dumenil, A.M., Bakker, A.H., Maehr, R., Fiebiger, E., Overkleeft, H.S.,
Rosemblatt, M., Ploegh, H.L., and Lagaudriere-Gesbert, C. (2002). Analysis of
protease activity in live antigen-presenting cells shows regulation of the phag-
osomal proteolytic contents during dendritic cell activation. J. Exp. Med. 196,
529–540.
Ling, Y.M., Shaw, M.H., Ayala, C., Coppens, I., Taylor, G.A., Ferguson, D.J.,
and Yap, G.S. (2006). Vacuolar and plasma membrane stripping and autopha-
gic elimination of Toxoplasma gondii in primed effector macrophages. J. Exp.
Med. 203, 2063–2071.
MacMicking, J.D. (2004). IFN-inducible GTPases and immunity to intracellular
pathogens. Trends Immunol. 25, 601–609.
MacMicking, J.D., Taylor, G.A., and McKinney, J.D. (2003). Immune control of
tuberculosis by IFN-gamma-inducible LRG-47. Science 302, 654–659.
Maroof, A., English, N.R., Bedford, P.A., Gabrilovich, D.I., and Knight, S.C.
(2005). Developing dendritic cells become ‘lacy’ cells packed with fat and
glycogen. Immunology 115, 473–483.
Martens, S., Parvanova, I., Zerrahn, J., Griffiths, G., Schell, G., Reichmann, G.,
and Howard, J.C. (2005). Disruption of Toxoplasma gondii parasitophorous
vacuoles by the mouse p47-resistance GTPases. PLoS Pathog. 1, e24.
Norbury, C.C., Chambers, B.J., Prescott, A.R., Ljunggren, H.G., and Watts, C.
(1997). Constitutive macropinocytosis allows TAP-dependent major histo-
compatibility complex class I presentation of exogenous soluble antigen by
bone marrow-derived dendritic cells. Eur. J. Immunol. 27, 280–288.
Paul, A., Chang, B.H., Li, L., Yechoor, V.K., and Chan, L. (2008). Deficiency of
adipose differentiation-related protein impairs foam cell formation and
protects against atherosclerosis. Circ. Res. 102, 1492–1501.
Ploegh, H.L. (2007). A lipid-based model for the creation of an escape hatch
from the endoplasmic reticulum. Nature 448, 435–438.244 Immunity 31, 232–244, August 21, 2009 ª2009 Elsevier Inc.Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno,
M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., and Amigor-
ena, S. (1999). Fcgamma receptor-mediated induction of dendritic cell matu-
ration and major histocompatibility complex class I-restricted antigen presen-
tation after immune complex internalization. J. Exp. Med. 189, 371–380.
Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P., and Ami-
gorena, S. (1999). Selective transport of internalized antigens to the cytosol
for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362–368.
Savina, A., Jancic, C., Hugues, S., Guermonprez, P., Vargas, P., Moura, I.C.,
Lennon-Dumenil, A.M., Seabra, M.C., Raposo, G., and Amigorena, S.
(2006). NOX2 controls phagosomal pH to regulate antigen processing during
crosspresentation by dendritic cells. Cell 126, 205–218.
Schnorrer, P., Behrens, G.M., Wilson, N.S., Pooley, J.L., Smith, C.M.,
El-Sukkari, D., Davey, G., Kupresanin, F., Li, M., Maraskovsky, E., et al.
(2006). The dominant role of CD8+ dendritic cells in cross-presentation is
not dictated by antigen capture. Proc. Natl. Acad. Sci. USA 103, 10729–10734.
Schulz, O., Diebold, S.S., Chen, M., Naslund, T.I., Nolte, M.A., Alexopoulou, L.,
Azuma, Y.T., Flavell, R.A., Liljestrom, P., and Reis e Sousa, C. (2005). Toll-like
receptor 3 promotes cross-priming to virus-infected cells. Nature 433,
887–892.
Shenoy, A.R., Kim, B.H., Choi, H.P., Matsuzawa, T., Tiwari, S., and MacMick-
ing, J.D. (2007). Emerging themes in IFN-gamma-induced macrophage immu-
nity by the p47 and p65 GTPase families. Immunobiology 212, 771–784.
Steinman, R.M., and Cohn, Z.A. (1973). Identification of a novel cell type in
peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distri-
bution. J. Exp. Med. 137, 1142–1162.
Steinman, R.M., and Nussenzweig, M.C. (2002). Avoiding horror autotoxicus:
The importance of dendritic cells in peripheral T cell tolerance. Proc. Natl.
Acad. Sci. USA 99, 351–358.
Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. (2003). Tolerogenic
dendritic cells. Annu. Rev. Immunol. 21, 685–711.
Tabata, N., Ito, M., Tomoda, H., and Omura, S. (1997). Xanthohumols, diacyl-
glycerol acyltransferase inhibitors, from Humulus lupulus. Phytochemistry 46,
683–687.
Taylor, G.A., Jeffers, M., Largaespada, D.A., Jenkins, N.A., Copeland, N.G.,
and Woude, G.F. (1996). Identification of a novel GTPase, the inducibly
expressed GTPase, that accumulates in response to interferon gamma.
J. Biol. Chem. 271, 20399–20405.
Taylor, G.A., Stauber, R., Rulong, S., Hudson, E., Pei, V., Pavlakis, G.N.,
Resau, J.H., and Vande Woude, G.F. (1997). The inducibly expressed GTPase
localizes to the endoplasmic reticulum, independently of GTP binding. J. Biol.
Chem. 272, 10639–10645.
Taylor, G.A., Collazo, C.M., Yap, G.S., Nguyen, K., Gregorio, T.A., Taylor, L.S.,
Eagleson, B., Secrest, L., Southon, E.A., Reid, S.W., et al. (2000). Pathogen-
specific loss of host resistance in mice lacking the IFN-gamma-inducible
gene IGTP. Proc. Natl. Acad. Sci. USA 97, 751–755.
Tiwari, S., Choi, H.P., Matsuzawa, T., Pypaert, M., and MacMicking, J.D.
(2009). Targeting of the GTPase Irgm1 to the phagosomal membrane via
PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3) promotes immunity to mycobacteria.
Nat. Immunol. 10, 907–917.
Trombetta, E.S., Ebersold, M., Garrett, W., Pypaert, M., and Mellman, I. (2003).
Activation of lysosomal function during dendritic cell maturation. Science 299,
1400–1403.
Yamaguchi, T., Omatsu, N., Omukae, A., and Osumi, T. (2006). Analysis of
interaction partners for perilipin and ADRP on lipid droplets. Mol. Cell. Bio-
chem. 284, 167–173.
